Fate Therapeutics (FATE) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $1.79, -7.25% vs the prior close of $1.93.
- Volume 1.38M shares, 0.9x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
FATE slides 7.3% to $1.79, a 3-month low, 5 down days in a row. Closed at $1.79, -7.25% vs the prior close of $1.93. Day range $1.78–$1.95, opened at $1.94.
FATE daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — FATE slides 7.3% to $1.79, a 3-month low, 5 down days in a row
- Closed at $1.79, -7.25% vs the prior close of $1.93. Day range $1.78–$1.95, opened at $1.94.
- Volume was 1.38M shares, 0.9x its 50-day average of 1.53M.
- Price is -25.5% vs its 50-day average ($2.40) and -6.1% vs its 200-day average ($1.91).
- 52-week range $0.95–$3.23; today's close sits at 37% of that range, 44.6% below the 52-week high.
- That makes 5 straight losses.
Oct 15, 2026 — FATE dips 0.5% to $1.93, a 3-month low, 4 down days in a row
- Closed at $1.93, -0.52% vs the prior close of $1.94. Day range $1.91–$2.00, opened at $1.96.
- Volume was 1.16M shares, 0.7x its 50-day average of 1.57M.
- Price is -20.1% vs its 50-day average ($2.42) and +1.5% vs its 200-day average ($1.90).
- 52-week range $0.95–$3.23; today's close sits at 43% of that range, 40.2% below the 52-week high.
- That makes 4 straight losses.
Oct 14, 2026 — FATE dips 3.0% to $1.94, a 3-month low, 3 down days in a row
- Closed at $1.94, -3.00% vs the prior close of $2.00. Day range $1.89–$1.99, opened at $1.95.
- Volume was 1.67M shares, 1.0x its 50-day average of 1.67M.
- Price is -20.2% vs its 50-day average ($2.43) and +2.3% vs its 200-day average ($1.90).
- 52-week range $0.95–$3.23; today's close sits at 43% of that range, 39.9% below the 52-week high.
- That makes 3 straight losses.
Oct 13, 2026 — FATE slides 6.1% to $2.00, a 3-month low
- Closed at $2.00, -6.10% vs the prior close of $2.13. Day range $1.98–$2.13, opened at $2.13.
- Volume was 953.50K shares, 0.6x its 50-day average of 1.68M — lighter than usual.
- Price is -18.1% vs its 50-day average ($2.44) and +5.7% vs its 200-day average ($1.89).
- 52-week range $0.95–$3.23; today's close sits at 46% of that range, 38.1% below the 52-week high.
Oct 12, 2026 — FATE dips 2.3% to $2.13
- Closed at $2.13, -2.29% vs the prior close of $2.18. Day range $2.10–$2.18, opened at $2.13.
- Volume was 616.80K shares, 0.4x its 50-day average of 1.69M — lighter than usual.
- Price is -13.1% vs its 50-day average ($2.45) and +12.9% vs its 200-day average ($1.89).
- 52-week range $0.95–$3.23; today's close sits at 52% of that range, 34.1% below the 52-week high.
Oct 9, 2026 — FATE rises 2.3% to $2.18
- Closed at $2.18, +2.35% vs the prior close of $2.13. Day range $2.10–$2.28, opened at $2.13.
- Volume was 770.70K shares, 0.5x its 50-day average of 1.71M — lighter than usual.
- Price is -11.3% vs its 50-day average ($2.46) and +15.9% vs its 200-day average ($1.88).
- 52-week range $0.95–$3.23; today's close sits at 54% of that range, 32.5% below the 52-week high.
Oct 8, 2026 — FATE dips 0.9% to $2.13, a 3-month low, 3 down days in a row
- Closed at $2.13, -0.93% vs the prior close of $2.15. Day range $2.03–$2.13, opened at $2.12.
- Volume was 1.48M shares, 0.9x its 50-day average of 1.70M.
- Price is -13.6% vs its 50-day average ($2.47) and +13.6% vs its 200-day average ($1.88).
- 52-week range $0.95–$3.23; today's close sits at 52% of that range, 34.1% below the 52-week high.
- That makes 3 straight losses.
Oct 7, 2026 — FATE slides 6.1% to $2.15, a 3-month low
- Closed at $2.15, -6.11% vs the prior close of $2.29. Day range $2.14–$2.30, opened at $2.28.
- Volume was 862.30K shares, 0.5x its 50-day average of 1.72M — lighter than usual.
- Price is -13.0% vs its 50-day average ($2.47) and +15.0% vs its 200-day average ($1.87).
- 52-week range $0.95–$3.23; today's close sits at 53% of that range, 33.4% below the 52-week high.
Oct 6, 2026 — FATE slides 5.8% to $2.29, a 3-month low
- Closed at $2.29, -5.76% vs the prior close of $2.43. Day range $2.29–$2.49, opened at $2.43.
- Volume was 1.13M shares, 0.7x its 50-day average of 1.71M.
- Price is -7.4% vs its 50-day average ($2.47) and +22.8% vs its 200-day average ($1.86).
- 52-week range $0.95–$3.23; today's close sits at 59% of that range, 29.1% below the 52-week high.
Oct 5, 2026 — FATE jumps 4.7% to $2.43 on 2.0x normal volume
- Closed at $2.43, +4.74% vs the prior close of $2.32. Day range $2.29–$2.58, opened at $2.32.
- Volume was 3.38M shares, 2.0x its 50-day average of 1.66M — unusually heavy trading.
- Price is -1.9% vs its 50-day average ($2.48) and +30.8% vs its 200-day average ($1.86).
- 52-week range $0.95–$3.23; today's close sits at 65% of that range, 24.8% below the 52-week high.
Oct 2, 2026 — FATE rises 0.9% to $2.32
- Closed at $2.32, +0.87% vs the prior close of $2.30. Day range $2.27–$2.36, opened at $2.34.
- Volume was 657.00K shares, 0.4x its 50-day average of 1.68M — lighter than usual.
- Price is -6.3% vs its 50-day average ($2.48) and +25.3% vs its 200-day average ($1.85).
- 52-week range $0.95–$3.23; today's close sits at 60% of that range, 28.2% below the 52-week high.
FATE latest news & SEC filings
Every SEC filing by or about FATE in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Sep 28, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Aug 13, 2026 · Form S-8 — Employee share plan registration
Registration of shares for employee stock plans (S-8)
Aug 13, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $2.08M (prior year $1.91M) (+9.2% vs Jun 30, 2025)
- Net income: -$30.16M (prior year -$34.07M) (loss narrowed vs Jun 30, 2025)
- Diluted EPS: -$0.25 (prior year -$0.29) (loss narrowed vs Jun 30, 2025)
Aug 13, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Aug 5, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Tahl Cindy sold 38,800 shares at $2.46 (≈$95.45K) on Aug 4, 2026
- Tahl Cindy sold 38,800 shares at $2.46 (≈$95.45K) on Aug 4, 2026
- Tahl Cindy sold 38,800 shares at $2.46 (≈$95.45K) on Aug 4, 2026
- Tahl Cindy sold 38,800 shares at $2.46 (≈$95.45K) on Aug 4, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 5, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Valamehr Bahram sold 43,947 shares at $2.46 (≈$108.11K) on Aug 4, 2026
- Valamehr Bahram sold 43,947 shares at $2.46 (≈$108.11K) on Aug 4, 2026
- Valamehr Bahram sold 43,947 shares at $2.46 (≈$108.11K) on Aug 4, 2026
- Valamehr Bahram sold 43,947 shares at $2.46 (≈$108.11K) on Aug 4, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 4, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Aug 4, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Jul 8, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Things to know before you trade FATE
- Last results release: Aug 13, 2026 (8-K Item 2.02). Previous ones: May 13, 2026, Feb 26, 2026, Nov 13, 2025. Based on that rhythm, the next report is likely around Nov 12, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 2.87% (largest 7.3%).
- Liquidity: about 1.35M shares (≈$2.41M) trade per day on average.
- 52-week position: $1.79 vs a range of $0.95–$3.23 (37% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 24 sales; latest: Bahram Valamehr sold 43,947 shares on Aug 4, 2026.
- Latest filings: 8-K Sep 28, 2026; 10-Q Aug 13, 2026; 8-K Aug 13, 2026.
- Share count: 119.82M shares outstanding (Aug 6, 2026), +3.9% vs a year earlier.
- Listing: Nasdaq · industry: Biological Products, (No Diagnostic Substances).
FATE market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 1.94 | 1.95 | 1.78 | 1.79 | 1.38M |
| Oct 15, 2026 | 1.96 | 2.00 | 1.91 | 1.93 | 1.16M |
| Oct 14, 2026 | 1.95 | 1.99 | 1.89 | 1.94 | 1.67M |
| Oct 13, 2026 | 2.13 | 2.13 | 1.98 | 2.00 | 953.50K |
| Oct 12, 2026 | 2.13 | 2.18 | 2.10 | 2.13 | 616.80K |
| Oct 9, 2026 | 2.13 | 2.28 | 2.10 | 2.18 | 770.70K |
| Oct 8, 2026 | 2.12 | 2.13 | 2.03 | 2.13 | 1.48M |
| Oct 7, 2026 | 2.28 | 2.30 | 2.14 | 2.15 | 862.30K |
| Oct 6, 2026 | 2.43 | 2.49 | 2.29 | 2.29 | 1.13M |
| Oct 5, 2026 | 2.32 | 2.58 | 2.29 | 2.43 | 3.38M |
| Oct 2, 2026 | 2.34 | 2.36 | 2.27 | 2.32 | 657.00K |
| Oct 1, 2026 | 2.37 | 2.39 | 2.29 | 2.30 | 811.70K |
| Sep 30, 2026 | 2.40 | 2.50 | 2.36 | 2.37 | 1.08M |
| Sep 29, 2026 | 2.37 | 2.41 | 2.29 | 2.38 | 1.44M |
| Sep 28, 2026 | 2.30 | 2.42 | 2.27 | 2.38 | 1.16M |
| Sep 25, 2026 | 2.34 | 2.47 | 2.27 | 2.35 | 3.39M |
| Sep 24, 2026 | 2.43 | 2.43 | 2.27 | 2.33 | 1.18M |
| Sep 23, 2026 | 2.57 | 2.59 | 2.43 | 2.43 | 905.90K |
| Sep 22, 2026 | 2.55 | 2.63 | 2.51 | 2.58 | 1.66M |
| Sep 21, 2026 | 2.52 | 2.58 | 2.44 | 2.53 | 1.27M |
About Fate Therapeutics
Fate Therapeutics (FATE) is listed on the Nasdaq and classified by the SEC under “Biological Products, (No Diagnostic Substances)”. Its business address is in SAN DIEGO, CA. Fiscal year ends December 31. SEC CIK 1434316.
FATE board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Matt Abernethy | Director | Jun 15, 2026 |
| Shefali Agarwal | Director | Jun 15, 2026 |
| Robert S Epstein | Director | Jun 15, 2026 |
| Jeremy Green | Director | Jun 15, 2026 |
| Laura Hamill | Director | Jun 15, 2026 |
| Karin Jooss | Director | Jun 15, 2026 |
| Michael Stewart Lee | Director | Jun 15, 2026 |
| William H Rastetter | Director | Jun 15, 2026 |
| Ii Master Fund, L.P. Redco | Director | Apr 23, 2026 |
| Group, Llc Redmile | Director | Jun 15, 2026 |
| Bahram Valamehr | President and CEO | Aug 5, 2026 |
| Yuan Xu | Director | Jun 15, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Kamal Adawi | Chief Financial Officer | Jan 16, 2026 |
| Cindy Tahl | See Remarks | Aug 5, 2026 |
| Bahram Valamehr | President and CEO | Aug 5, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Aug 4, 2026 | Bahram Valamehr | Sale | 43,947 | $2.46 |
| Aug 4, 2026 | Bahram Valamehr | Sale | 43,947 | $2.46 |
| Aug 4, 2026 | Bahram Valamehr | Sale | 43,947 | $2.46 |
| Aug 4, 2026 | Bahram Valamehr | Sale | 43,947 | $2.46 |
| Aug 4, 2026 | Cindy Tahl | Sale | 38,800 | $2.46 |
| Aug 4, 2026 | Cindy Tahl | Sale | 38,800 | $2.46 |
| Aug 4, 2026 | Cindy Tahl | Sale | 38,800 | $2.46 |
| Aug 4, 2026 | Cindy Tahl | Sale | 38,800 | $2.46 |
| May 20, 2026 | Cindy Tahl | Sale | 25,590 | $1.88 |
| May 20, 2026 | Cindy Tahl | Sale | 25,590 | $1.88 |
| May 20, 2026 | Cindy Tahl | Sale | 25,590 | $1.88 |
| May 20, 2026 | Cindy Tahl | Sale | 25,590 | $1.88 |
| May 20, 2026 | Bahram Valamehr | Sale | 28,946 | $1.88 |
| May 20, 2026 | Bahram Valamehr | Sale | 28,946 | $1.88 |
| May 20, 2026 | Bahram Valamehr | Sale | 28,946 | $1.88 |
FATE financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $6.65M | $-136.31M | -1.15 | $-106.08M |
| Dec 31, 2024 | $13.63M | $-186.26M | -1.64 | $-122.87M |
| Dec 31, 2023 | $63.53M | $-160.93M | -1.64 | $-132.26M |
| Dec 31, 2022 | $96.30M | $-281.72M | -2.91 | $-248.21M |
| Dec 31, 2021 | $55.85M | $-212.15M | -2.24 | $-162.87M |
Latest balance sheet: total assets $260.10M, total liabilities $—, cash $32.43M (as of Jun 30, 2026).
FATE earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 13, 2026 | 8-K Item 2.02 (results) | $2.52 |
| May 13, 2026 | 8-K Item 2.02 (results) | $2.14 |
| Feb 26, 2026 | 8-K Item 2.02 (results) | $1.56 |
| Nov 13, 2025 | 8-K Item 2.02 (results) | $0.99 |
| Aug 12, 2025 | 8-K Item 2.02 (results) | $0.94 |
| May 13, 2025 | 8-K Item 2.02 (results) | $1.00 |
| Mar 5, 2025 | 8-K Item 2.02 (results) | $0.91 |
| Nov 12, 2024 | 8-K Item 2.02 (results) | $2.38 |
| Aug 13, 2024 | 8-K Item 2.02 (results) | — |
| May 9, 2024 | 8-K Item 2.02 (results) | — |
| Feb 26, 2024 | 8-K Item 2.02 (results) | — |
| Nov 8, 2023 | 8-K Item 2.02 (results) | — |
Related stocks · Biological Products, (No Diagnostic Substances)
Moderna (MRNA)Amgen (AMGN)Gilead Sciences (GILD)Twist Bioscience (TWST)Revolution Medicines (RVMD)Argenx Se (ARGX)Kodiak Sciences (KOD)Greenland Mines (GRML)Halozyme Therapeutics (HALO)Biogen (BIIB)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on FATE
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.